Under a 2007 agreement between the two companies, Micromet and Nycomed are developing MT203, a human anti-GM-CSF antibody that may be useful for the treatment of various inflammatory and autoimmune diseases.
Preclinical studies support development of MT203 for the treatment of rheumatoid arthritis and several other diseases, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.
Jens Hennecke, senior vice president of business development at Micromet, said: “Since the start of our collaboration with Nycomed in 2007, we have made excellent progress on the preclinical development of MT203. The filing of the clinical trial application represents an important milestone and we are looking forward to the start of clinical trials with MT203.”